Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (DE:HDP1)
FRANKFURT:HDP1
RESEARCH TOOLSreports
Arrowhead Pharmaceuticals (HDP1) Stock Price & Analysis
2 Followers
HDP1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€19.52 - €36.69
Previous Close€26.16
Volume0.00
Average Volume (3M)N/A
Market Cap
€3.29B
Enterprise Value€3.05B
Total Cash (Recent Filing)$395.41M
Total Debt (Recent Filing)$118.92M
Price to Earnings (P/E)―
Beta0.57
Next Earnings
Aug 08, 2024EPS Estimate
-€0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding124,200,230
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)6.68
Price to Sales (P/S)11.37
Price to Cash Flow (P/CF)-8.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue85.93
Enterprise Value/Gross Profit12.66
Enterprise Value/Ebitda-6.99
Forecast
1Y Price Target
€42.12Price Target Upside61.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Arrowhead Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe ARO-RAGE program has shown a favorable safety profile with no detrimental effects on lung function, supporting its advancement to a more robust Phase 2 program.
Pipeline And PartnershipsArrowhead's pulmonary pipeline continues to advance as a clear leader in the RNA therapeutics space and may soon unlock substantial value for shareholders.
Preclinical DataPreclinical data suggests the potential for ARO-IAV as a novel first-in-class approach for the treatment of highly pathogenic influenza A infections, including H5N1 bird flu.
Bears Say
Clinical DevelopmentManagement downplayed the translatability of biomarker data from an ongoing RAGE study, deciding to move to Ph2a without waiting for this data.
Financial PerformanceKey value drivers are seen as emerging likely starting in 2026, thus awaiting validation of those opportunities to understand the longer-term growth profile of the company.
Product PerformancePlozasiran treatment led to a rise in LDL cholesterol, which is not a desired treatment outcome even if TGs decrease.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.89% Other Institutional Investors
99.11% Public Companies and
Individual Investors
HDP1 FAQ
What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
Arrowhead Pharmaceuticals lowest stock price was €19.52 and its highest was €36.69 in the past 12 months.
What is Arrowhead Pharmaceuticals’s market cap?
Currently, no data Available
When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
Arrowhead Pharmaceuticals’s upcoming earnings report date is Aug 08, 2024 which is in 15 days.
How were Arrowhead Pharmaceuticals’s earnings last quarter?
Arrowhead Pharmaceuticals released its earnings results on May 09, 2024. The company reported -€0.936 earnings per share for the quarter, missing the consensus estimate of -€0.433 by -€0.503.
Is Arrowhead Pharmaceuticals overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals pay dividends?
Arrowhead Pharmaceuticals does not currently pay dividends.
What is Arrowhead Pharmaceuticals’s EPS estimate?
Arrowhead Pharmaceuticals’s EPS estimate is -€0.49.
How many shares outstanding does Arrowhead Pharmaceuticals have?
Currently, no data Available
What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
Arrowhead Pharmaceuticals reported an EPS of -€0.936 in its last earnings report, missing expectations of -€0.433. Following the earnings report the stock price went down -3.308%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
Among the largest hedge funds holding Arrowhead Pharmaceuticals’s share is Slate Path Capital LP. It holds Arrowhead Pharmaceuticals’s shares valued at 118M.
---
Arrowhead Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€42.12 (61.03% Upside)
€42.12 (61.03% Upside)
Blogger Sentiment
Bullish
DE:HDP1 Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.23%
12-Months-Change
Fundamentals
Return on Equity
-101.18%
Trailing 12-Months
Asset Growth
7.16%
Trailing 12-Months
Company Description
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
---
HDP1 Earnings Call
Q2 2024
0:00 / 0:00
---
HDP1 Stock 12 Month Forecast
Average Price Target
€42.12
▲(61.03% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Alnylam Pharma
―
Arcturus Therapeutics
―
Arvinas Holding Company
―
Exelixis
―
Best Analysts Covering HDP1
1 Year
1 Year Success Rate
21/36 ratings generated profit
1 Year Average Return
+37.79%
reiterated a buy rating 2 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +37.79% per trade.
---